Document Classification

Section Type: RESULTS

Text: Patients with elevated serum TIMP-1 had a significantly reduced objective response rate (19. 2 % v 30. 6 % ; odds ratio, 0. 54 ; P =. 01), duration of response (median, 15. 5 v 26. 2 months ; P =. 001), time to treatment progression (TTP ; median, 4. 5 v 9. 2 months ; HR, 1. 78 ; P =. 0001), time to treatment failure (median, 3. 5 v 9. 0 months ; HR, 1. 77 ; P =. 0001), and overall survival (median, 20. 3 v 35. 8 months ; HR, 1. 77 ; P =. 0001) compared with patients with normal pretreatment TIMP-1 levels.